January 2015—Quest Diagnostics now offers BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.
BRCAvantage Plus screens for point mutations, deletions, and duplications in the BRCA1 and BRCA2 genes and in five additional genes—TP53, PTEN, CDH1, STK11, and PALB2. A key feature of BRCAvantage Plus, according to a company statement, is that physicians can order single gene tests as well as a comprehensive panel, depending on the specific clinical and family history. An additional reflex option automatically tests the five non-BRCA genes in cases where initial BRCA1 and BRCA2 mutation testing produces a negative result.
Quest Diagnostics, 866-436-3463